

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

IMPORT AND SERVICE AGREEMENT WITH PFIZER INTERNATIONAL TRADING (SHANGHAI) LTD.

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 17 February 2014, Essex Medipharma entered into the Import and Service Agreement with Pfizer and an independent third party in relation to the importation, distribution and promotion of the Pfizer Eye Drops in China.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 17 February 2014, 珠海億勝醫藥有限公司 (Essex Medipharma (Zhuhai) Co., Ltd.*) (“**Essex Medipharma**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred to as the “**Group**”) entered into an import and service agreement and two supplemental import and service agreements with Pfizer International Trading (Shanghai) Limited (“**Pfizer**”) and a memorandum of understanding with Pfizer and an independent third party (collectively the “**Import and Service Agreement**”). Pursuant to the Import and Service Agreement, among other things, Essex Medipharma is appointed and/or authorized by Pfizer as its exclusive importer, distributor and promoter for Xalatan® eye drops and Xalacom® eye drops (collectively the “**Pfizer Eye Drops**”) in the Mainland China (excluding Taiwan, Hong Kong and Macau) (“**China**”). The Import and Service Agreement is for a term of five years from February 2014 and shall be automatically extended for three years unless otherwise terminated by either party.

The Pfizer Eye Drops are medicines to lower raised pressure within the eye.

Essex Medipharma is principally engaged in the marketing and distribution of pharmaceutical products.

The establishment of business relationship with Pfizer will expand the range of the Group’s eye drops products, benefiting the Group in striving for sustainable growth in the ophthalmology arena in China.

By order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 17 February 2014

Executive directors of the Company as at the date of this announcement are Mr Ngiam Mia Je Patrick, Mr Fang Haizhou and Mr Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr Fung Chi Ying, Mr Mauffrey Benoit Jean Marie and Ms Yeow Mee Mooi.

* denotes an English translation of a Chinese name